Mati Therapeutics
PrivateLast Round
Seed Round
Jul 2, 2026
Total Funding Raised
$12.05M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mati Therapeutics is a healthcare company developing a non-invasive sustained drug delivery platform, the Evolute® Punctal Plug Delivery System, to treat ocular diseases such as glaucoma.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mati Therapeutics Comparables
Compare Mati Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediPrint Ophthalmics | 83% | |
| INEYE THERAPEUTICS S.A. | 82% | |
| Ocular Therapeutix Inc | 80% | |
Mati Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jul 2, 2026 | ||||
| Series A | Oct 8, 2025 | ||||
| VC Round | Apr 8, 2013 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 123% MoM, reaching 2.1K.
- Jul 2, 2026
Raised $2.65M in a Seed Round.
Mati Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mati Therapeutics's valuation, stock price, and market status.